Literature DB >> 8911290

Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario.

M D Sergeant1, P G Hodgetts, M Godwin, D M Walker, P McHenry.   

Abstract

OBJECTIVE: To determine the attitudes, knowledge and practices of family medicine residents relating to the pharmaceutical industry and to assess the effectiveness of existing guidelines on appropriate interactions with the pharmaceutical industry.
DESIGN: Survey by mailed questionnaire.
SETTING: Ontario. PARTICIPANTS: All 262 second-year family medicine residents in Ontario (seven centres); 226 (86.3%) responded.
RESULTS: Fifty-two (23.0%) of the residents who responded stated that they had read the CMA policy statement on appropriate interactions between physicians and the pharmaceutical industry. A total of 124 (54.9%) stated that they would attend a private dinner paid for by a pharmaceutical representative; the proportion was not significantly reduced among those who had read the CMA guidelines, which prohibit the acceptance of personal gifts. In all, 186 (82.3%) reported that they would like the opportunity to interact with pharmaceutical representatives in an educational setting, even though several programs now discourage these interactions. Approximately three quarters (172/226 [76.1%]) of the residents indicated that they plan to see pharmaceutical representatives in their future practice. Residents at Centre 2 were significantly more critical of the pharmaceutical industry than those from the other centres. Overall, being aware of, and familiar with, departmental policy or CMA policy on interactions with the pharmaceutical industry did not affect the residents' attitudes or intended future practices.
CONCLUSION: The presence of guidelines concerning physicians' interactions with the pharmaceutical industry does not appear to have a significant impact on family medicine residents in Ontario.

Entities:  

Keywords:  Canadian Medical Association; Empirical Approach; Health Care and Public Health

Mesh:

Year:  1996        PMID: 8911290      PMCID: PMC1335065     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  4 in total

1.  Changes in drug prescribing patterns related to commercial company funding of continuing medical education.

Authors:  M A Bowman; D L Pearle
Journal:  J Contin Educ Health Prof       Date:  1988       Impact factor: 1.355

2.  Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices.

Authors:  A D Bower; G L Burkett
Journal:  J Fam Pract       Date:  1987-06       Impact factor: 0.493

Review 3.  Interactions between physicians and the pharmaceutical industry: what does the literature say?

Authors:  J Lexchin
Journal:  CMAJ       Date:  1993-11-15       Impact factor: 8.262

4.  Doctors, drug companies, and gifts.

Authors:  M M Chren; C S Landefeld; T H Murray
Journal:  JAMA       Date:  1989 Dec 22-29       Impact factor: 56.272

  4 in total
  12 in total

1.  Teaching appropriate interactions with pharmaceutical company representatives: the impact of an innovative workshop on student attitudes.

Authors:  James L Wofford; Christopher A Ohl
Journal:  BMC Med Educ       Date:  2005-02-08       Impact factor: 2.463

Review 2.  Interactions between pharmaceutical representatives and doctors in training. A thematic review.

Authors:  Daniella A Zipkin; Michael A Steinman
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

3.  The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.

Authors:  Jathin Bandari; Robert M Turner; Bruce L Jacobs; David Canes; Ali Moinzadeh; Benjamin J Davies
Journal:  Urol Pract       Date:  2017-01

Review 4.  Bioethics for clinicians: 17. Conflict of interest in research, education and patient care.

Authors:  T Lemmens; P A Singer
Journal:  CMAJ       Date:  1998-10-20       Impact factor: 8.262

5.  Structured approach to pharmaceutical representatives. Family medicine residency program.

Authors:  S Kelcher; R Brownoff; L M Meadows
Journal:  Can Fam Physician       Date:  1998-05       Impact factor: 3.275

6.  Professional Conferences, Unprofessional Conduct.

Authors:  A C Anand
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Teaching trainees to negotiate research collaborations with industry: a mentorship model.

Authors:  David B Merrill; Ragy R Girgis; Lincoln C Bickford; Stanislav R Vorel; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2010-04       Impact factor: 18.112

8.  Japanese practicing physicians' relationships with pharmaceutical representatives: a national survey.

Authors:  Sayaka Saito; Kei Mukohara; Seiji Bito
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

9.  Physicians and drug representatives: exploring the dynamics of the relationship.

Authors:  Susan Chimonas; Troyen A Brennan; David J Rothman
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

10.  Characteristics and impact of drug detailing for gabapentin.

Authors:  Michael A Steinman; G Michael Harper; Mary-Margaret Chren; C Seth Landefeld; Lisa A Bero
Journal:  PLoS Med       Date:  2007-04       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.